DOCSLIB.ORG

Glycan Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Glycan Analysis Agilent Biocolumns Glycan Analysis Application Compendium Contents Background 2 Getting Started 3 How to Guide - Glycan Mapping 4 Featured Application Notes 12 Fast and Efficient HILIC Methods for Improved Analysis of Complex Glycan Structures - 5991-4896EN 12 N-Glycan Analysis of mAbs and Other Glycoproteins with UHPLC and Fluorescence Detection - 5991-5253EN 17 Agilent Solutions for High-throughput N-linked Glycan Profiling from Biotherapeutics - 5991-6904EN 25 Additional Application Notes 30 More Information 30 1 Glycan Analysis Background Glycosylation is an important post-translational modification as these sugar molecules play a key role in protein recognition and biotherapeutic efficacy. Human glycosylation profiles follow a typical antenna-like pattern and it is the goal of recombinant protein manufacturers to try to replicate that profile using cell culture. Mammalian cell lines are required, but the glycosylation pathway is complex, and not all clones will generate the necessary glycan profile. Regulatory authorities recognize this as a major challenge and provide instructions in how to determine the glycan fingerprint. This involves the use of a specific enzyme, PNGase F, to cleave N-linked glycans, labeling them to increase detection sensitivity, and then separating them using HILIC chromatography columns (often in combination with a fluorescence detector, although mass spectrometry may also be used). Agilent provides a kit containing all the components needed to manually perform the deglycosylation and labeling reaction with 2 aminobenzoic acid (2AB). Alternatively, much higher throughput can be obtained using a fully automated AssayMAP platform capable of handling a greater number of samples in a fraction of the time. This approach is illustrated in the application note featured on page 166. Return to Contents Section 2 Getting Started HILIC, or hydrophilic interaction chromatography, uses H2O reversed-phase type eluents with gradients starting at high H2O H2O Glycan Analysis organic solvent content. The mechanism of interaction of H O 2 analytes with the stationary phase is a partitioning from the high organic eluent into the aqueous layer present on the surface of the stationary phase. Water is also the strong eluting solvent. It is therefore important to minimize Hydrophilic interaction chromatography the amount of water present in the sample matrix and to allow sufficient time for the column to re-equilibrate Fast, high-resolution, reproducible and stabilize at the end of each gradient. Following the glycan separation protocol contained in the sample preparation kit should ensure the 2AB labeled N-glycans are ready for analysis. AdvanceBio Glycan Mapping columns are available in superficially porous 2.7 µm columns suitable for use on AdvanceBio Glycan Mapping all HPLC instruments, or in fully porous 1.8 µm columns An amide HILIC column designed for use on highly optimized UHPLC instruments. Appropriate method conditions to achieve the optimum Attribute Advantage resolution for closely related glycan structures can be 2.7 µm superficially High resolution at low found in the Workflow "How-To" guides detailed in this porous particle back pressure section. 1.8 µm totally porous Maximum resolution particles Fluorescence and MS Easy method transfer compatible 3 Return to Contents Section Glycan Mapping: A "How-To" Guide Introduction Post-translational modifications to the primary amino acid sequence, including glycosylation, have functional consequences and can impact efficacy and immunogenicity of a biopharmaceutical. The structure of the glycan also contributes to the half-life of the protein in plasma and the ability of the monoclonal antibody to trigger the immune response required for efficacy. Regulatory authorities consider glycosylation to be one of the critical quality attributes of biomolecules. Therefore, it must be characterized and quantified, with acceptable ranges determined, as part of the development process for a glycoprotein innovator, biosimilar, or biobetter pharmaceuticals. Agilent AdvanceBio Glycan Mapping solution provides an optimized workflow designed to deliver reproducibility in the analysis of 2-aminobenzamide (2AB) labeled glycans, for accurate identification and quantification. Return to Contents Section 4 Sample Preparation - AdvanceBio N-Glycan Column Selection Sample Preparation Kit Agilent AdvanceBio Glycan Mapping columns are The mapping of the N-linked glycan component of a designed and manufactured to deliver fast, high glycoprotein, including monoclonal antibodies, requires resolution, reproducible glycan identification using the N-glycans to be enzymatically cleaved, using HILIC chromatography. AdvanceBio Glycan Mapping PNGase F, from the protein amino acid backbone. columns apply technology that optimizes results for MS The cleaved N-glycans can be analyzed by hydrophilic and fluorescence detection. Choose from two UHPLC interaction chromatography (HILIC) with MS detection. configurations: 2.7 µm superficially porous, for high Alternatively, N-glycans can labeled with the fluorophore, resolution and lower backpressure, or 1.8 µm for highest 2-aminobenzamide (2AB), and analyzed using HILIC resolution. chromatography followed by either fluorescence or MS Concentration of Final AA solution (pmol/µL) detection. AdvanceBio Amide bonded phase for rapid equilibration and AdvanceBio glycan sample preparation kits provide Glycan Mapping enhanced selectivity for glycans. all the reagents needed to prepare samples. The kit is 1.8 µm Based on a fully porous particle for high speed composed of four components that perform the steps separations and high throughput applications. Stability to 1200 bar for use with the Agilent 1290 Infinity II LC. of N-glycan release, N-glycan purification, labeling 2.7 µm Based on Poroshell technology to give a superficially with 2-aminobenzamide, and labeled glycan cleanup. porous particle with reduced diffusion distances to In addition, kits for each of the separate steps of the give high resolution separations at lower pressures workflow have separate part numbers for flexibility. The and enable the use of longer column lengths for increased separation efficiency. workflow yields samples that are suitable for analysis by liquid chromatography, typically by hydrophilic interaction chromatography (HILIC). Figure 1. Glycan mapping sample preparation workflow. 5 Return to Contents Section Speed of Analysis The AdvanceBio Glycan Mapping 1.8 µm columns provide high throughput N-glycan analysis where speed is the primary concern either due to the number of samples or to the immediate requirement for data. These columns deliver superior results in 40 % less time than the competition. Conditions Parameter Value Column A AdvanceBio Glycan Mapping, 2.1 × 150 mm, 1.8 μm Column B Competitor sub-2 μm glycan column Instrument Agilent 1290 Infinity LC with 1260 Infinity Flourescence Detection Column Temperature 55 °C Sample thermostat 105 °C Mobile Phase A: 100 mM NH4Formate. pH 4.5 B: ACN FLD Excitation = 260 Emission = 430 Injection Volume 2 μl in 70:30 ACN: 100mM NH4Formate Sample Agilent 2-AB labeled N-linked Human IgG glycan library (p/n5190-6996) Figure 2. The Agilent AdvanceBio Glycan Mapping column delivers better resolution, narrower bands, and higher peak capacity than the Resolution non-Agilent sub-2 µm column in a 2.1 x 150 mm configuration. High resolution separations are achieved using the AdvanceBio glycan mapping 2.7 µm media, in longer 250 mm columns. This increased resolution enables accurate quantitation of target glycans and changes to the protein glycosylation profile, which may have occurred during expression. Return to Contents Section 6 Ensure consistent results with glycan standards Flexible, high-performance LC instruments for performance testing and retention mapping Robust and easy to use: Missed information in the early stages of development The 100 % bio-inert Agilent 1260 Infinity II Bio-inert LC can cause major setbacks downstream. What’s delivers outstanding results with its low surface activity, more, production process inconsistency may lead to corrosion resistance, active seal wash, and quaternary changes in glycosylation, which can negatively impact buffer mixing. immunogenicity and efficacy. Agilent reference standards New Benchmarks in Efficiency: help you make sure that critical data have been captured, The Agilent 1290 Infinity II LC is the next generation in and that every workflow component is working optimally. UHPLC, providing maximum analytical, instrument, and Choose from two options: laboratory efficiency, with pressures up to 1300 bar and – Dextran ladder standard facilitates data analysis and flows up to 5 mL/min. reporting Better efficiency and interaction-free results: Agilent – IgG N-linked glycan standard confirms workflow bio-inert LC supplies improve chromatographic reliability efficiency with sharper peaks and high reproducibility. The two standards are available with the 2AB label attached and also without the 2AB label for use as sample preparation reference materials. Separation of a 2-AB labeled dextran ladder Conditions Parameter Value Column AdvanceBio Glycan Mapping, 859700-913 2.1 × 150 mm, 1.8 μm Mobile Phase A: 100 mM NH4Formate. pH 4.5 B: ACN FLD Excitation = 260 Emission = 430 Injection Volume 2 μl (10pmol total glycan/1 μl 75:25 ACN:water) Sample Agilent 2-AB labeled dextran ladder (p/n5190-6998) Figure 3. This analysis uses the agilent dextran ladder standard, together with an AdvanceBio Glycan
Load more

Recommended publications
  • Targeted Metabolic Labeling of Yeast N-Glycans with Unnatural Sugars
    Targeted metabolic labeling of yeast N-glycans with unnatural sugars Mark A. Breidenbacha, Jennifer E. G. Gallagherb, David S. Kingc, Brian P. Smarta, Peng Wua,2, and Carolyn R. Bertozzia,b,c,d,1 aDepartments of Chemistry; bMolecular and Cell Biology; and cHoward Hughes Medical Institute, University of California, Berkeley, CA 94720; and dThe Molecular Foundry, Lawrence Berkeley National Laboratory, Berkeley, CA 94720 Edited by David A. Tirrell, California Institute of Technology, Pasadena, CA, and approved December 23, 2009 (received for review September 30, 2009) Metabolic labeling of glycans with synthetic sugar analogs has and mass spectrometric analyses of proteins displaying the nonna- emerged as an attractive means for introducing nonnatural chemi- tural chemical functionality (5, 6). cal functionality into glycoproteins. However, the complexities of While existing glycan labeling methodology is suitable for stud- glycan biosynthesis prevent the installation of nonnatural moieties ies that require only stochastic insertion of analogs at low levels, at defined, predictable locations within glycoproteins at high levels the technique is inadequate for applications in which specific of incorporation. Here, we demonstrate that the conserved monosaccharides must be reliably targeted for metabolic replace- N-acetyglucosamine (GlcNAc) residues within chitobiose cores of ment. For example, high-efficiency and predictable installation of N-glycans in the model organism Saccharomyces cerevisiae can sugar analogs could dramatically facilitate biophysical studies of be specifically targeted for metabolic replacement by unnatural glycoprotein structure and function via site-specific introduction sugars. We introduced an exogenous GlcNAc salvage pathway into of fluorophores and heavy atoms. Unfortunately, site-specific me- yeast, allowing cells to metabolize GlcNAc provided as a supple- tabolic labeling of glycans is hindered by multiple factors.
    [Show full text]
  • High Affinity Biomolecular Interactions That Can Mediate Binding of Pathogenic Bacteria to Host Cells
    Glycan:glycan interactions: High affinity biomolecular interactions that can mediate binding of pathogenic bacteria to host cells Christopher J. Daya,1, Elizabeth N. Tranb, Evgeny A. Semchenkoa, Greg Trama, Lauren E. Hartley-Tassella, Preston S. K. Nga, Rebecca M. Kinga, Rachel Ulanovskya, Sarah McAtamneya, Michael A. Apicellac, Joe Tiralongoa, Renato Moronab,2, Victoria Korolika,2, and Michael P. Jenningsa,1,2 aInstitute for Glycomics, Griffith University Gold Coast Campus, Gold Coast, QLD 4222, Australia; bSchool of Biological Sciences, Department of Molecular and Cellular Biology, University of Adelaide, Adelaide, SA 5005, Australia; and cDepartment of Microbiology, University of Iowa, Iowa City, IA 52242 Edited by Rino Rappuoli, GSK Vaccines, Siena, Italy, and approved November 10, 2015 (received for review November 3, 2014) Cells from all domains of life express glycan structures attached to Interestingly, there are specific reports of several bacteria lipids and proteins on their surface, called glycoconjugates. Cell-to- expressing truncated surface polysaccharides and oligosaccharides cell contact mediated by glycan:glycan interactions have been that are significantly less adherent than wild-type equivalents considered to be low-affinity interactions that precede high- (10, 11), or that their adherence can be blocked by extracted affinity protein–glycan or protein–protein interactions. In several LOS/LPS (10), indicating a role for bacterial surface glycans in pathogenic bacteria, truncation of surface glycans, lipooligosac- adherence to host cells. This decreased adherence of rough strains charide (LOS), or lipopolysaccharide (LPS) have been reported to or blocking of adherence using the free lipooligosaccharide (LOS)/ significantly reduce bacterial adherence to host cells. Here, we lipopolysaccharide (LPS) in both cell-based and animal infection show that the saccharide component of LOS/LPS have direct, models has been noted in a range of Gram-negative bacteria in- high-affinity interactions with host glycans.
    [Show full text]
  • Metabolomics Analysis of Skeletal Muscles from FKRP-Deficient Mice
    www.nature.com/scientificreports OPEN Metabolomics Analysis of Skeletal Muscles from FKRP-Defcient Mice Indicates Improvement After Gene Received: 21 March 2019 Accepted: 28 June 2019 Replacement Therapy Published: xx xx xxxx Charles Harvey Vannoy 1, Victoria Leroy1, Katarzyna Broniowska2 & Qi Long Lu1 Muscular dystrophy-dystroglycanopathies comprise a heterogeneous and complex group of disorders caused by loss-of-function mutations in a multitude of genes that disrupt the glycobiology of α-dystroglycan, thereby afecting its ability to function as a receptor for extracellular matrix proteins. Of the various genes involved, FKRP codes for a protein that plays a critical role in the maturation of a novel glycan found only on α-dystroglycan. Yet despite knowing the genetic cause of FKRP-related dystroglycanopathies, the molecular pathogenesis of disease and metabolic response to therapeutic intervention has not been fully elucidated. To address these challenges, we utilized mass spectrometry- based metabolomics to generate comprehensive metabolite profles of skeletal muscle across diseased, treated, and normal states. Notably, FKRP-defcient mice elicit diverse metabolic abnormalities in biomarkers of extracellular matrix remodeling and/or aging, pentoses/pentitols, glycolytic intermediates, and lipid metabolism. More importantly, the restoration of FKRP protein activity following AAV-mediated gene therapy induced a substantial correction of these metabolic impairments. While interconnections of the afected molecular mechanisms remain unclear,
    [Show full text]
  • A Systematic Review on the Implications of O-Linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis
    cells Review A Systematic Review on the Implications of O-linked Glycan Branching and Truncating Enzymes on Cancer Progression and Metastasis 1, 1, 1 1,2,3, Rohitesh Gupta y, Frank Leon y, Sanchita Rauth , Surinder K. Batra * and Moorthy P. Ponnusamy 1,2,* 1 Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68105, USA; [email protected] (R.G.); [email protected] (F.L.); [email protected] (S.R.) 2 Fred and Pamela Buffett Cancer Center, Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE 681980-5900, USA 3 Department of Pathology and Microbiology, UNMC, Omaha, NE 68198-5900, USA * Correspondence: [email protected] (S.K.B.); [email protected] (M.P.P.); Tel.: +402-559-5455 (S.K.B.); +402-559-1170 (M.P.P.); Fax: +402-559-6650 (S.K.B. & M.P.P.) Equal contribution. y Received: 21 January 2020; Accepted: 12 February 2020; Published: 14 February 2020 Abstract: Glycosylation is the most commonly occurring post-translational modifications, and is believed to modify over 50% of all proteins. The process of glycan modification is directed by different glycosyltransferases, depending on the cell in which it is expressed. These small carbohydrate molecules consist of multiple glycan families that facilitate cell–cell interactions, protein interactions, and downstream signaling. An alteration of several types of O-glycan core structures have been implicated in multiple cancers, largely due to differential glycosyltransferase expression or activity. Consequently, aberrant O-linked glycosylation has been extensively demonstrated to affect biological function and protein integrity that directly result in cancer growth and progression of several diseases.
    [Show full text]
  • Biomolecule Purification, Characterization, and Analyses Biomolecule Purification, Characterization, and Analyses Characterization, Purification, Biomolecule
    Biomolecule Purification, Characterization, and Analyses Biomolecule Purification, Characterization, Analyses and “Quality is always about having a consistent product.” ~ Aoife Hayes, Technical Service Manager, Wexford, Ireland 239 Benchmarking, Method Development, and Troubleshooting: MassPREP Contents Peptide Standard .......................................................273 Phosphorylated Peptide Standards and Sample Preparation Kits..........................273 Innovative HPLC, UHPLC, Delta-Pak HPLC and UHPLC and UPLC Chemistry Consumables Columns ..............................................................................274 for Bioseparations ....................................................241 RapiGest SF Surfactant for Protein Digestions .....................................................275 Amino Acids ................................................................242 AccQ•Tag Ultra Derivatization Protein Separations ...............................................276 Reaction ..............................................................................242 ACQUITY UPLC SEC System Solution ..276 AccQ•Tag Amino Acid Analysis Turn Key Solution .......................................................243 Waters Insulin HMWP HPLC and UHPLC Columns .............................................278 Glycans and Glycoproteins ..............................247 XBridge Protein BEH SEC, 125Å, HILIC for Released 200Å, and 450Å Columns and N-Glycan Analysis .....................................................248 Protein Standard Test
    [Show full text]
  • Lacto Series Glycolipid Biosynthesis Impairs Α2-6 Sialylation On
    www.nature.com/scientificreports OPEN Altered (neo-) lacto series glycolipid biosynthesis impairs α2-6 sialylation on N-glycoproteins in Received: 24 November 2016 Accepted: 15 February 2017 ovarian cancer cells Published: 30 March 2017 Shahidul Alam1,2,*, Merrina Anugraham1,*, Yen-Lin Huang1, Reto S. Kohler1, Timm Hettich3, Katharina Winkelbach1, Yasmin Grether1, Mónica Núñez López1, Nailia Khasbiullina4, Nicolai V. Bovin4, Götz Schlotterbeck3 & Francis Jacob1,2 The (neo-) lacto series glycosphingolipids (nsGSLs) comprise of glycan epitopes that are present as blood group antigens, act as primary receptors for human pathogens and are also increasingly associated with malignant diseases. Beta-1, 3-N-acetyl-glucosaminyl-transferase 5 (B3GNT5) is suggested as the key glycosyltransferase for the biosynthesis of nsGSLs. In this study, we investigated the impact of CRISPR-Cas9 -mediated gene disruption of B3GNT5 (∆B3GNT5) on the expression of glycosphingolipids and N-glycoproteins by utilizing immunostaining and glycomics-based PGC-UHPLC- ESI-QTOF-MS/MS profiling.∆ B3GNT5 cells lost nsGSL expression coinciding with reduction of α2-6 sialylation on N-glycoproteins. In contrast, disruption of B4GALNT1, a glycosyltransferase for ganglio series GSLs did not affectα 2-6 sialylation on N-glycoproteins. We further profiled all knownα 2-6 sialyltransferase-encoding genes and showed that the loss of α2-6 sialylation is due to silencing of ST6GAL1 expression in ∆B3GNT5 cells. These results demonstrate that nsGSLs are part of a complex network affectingN -glycosylation in ovarian cancer cells. Glycosphingolipids (GSLs) have been shown to be essential in a wide variety of biological events - such as cell signalling, modification of insulin and EGF-receptor activities, and modulation of Notch ligand activity in Drosophila1.
    [Show full text]
  • Glycosylation States on Intact Proteins Determined by NMR Spectroscopy
    molecules Article Glycosylation States on Intact Proteins Determined by NMR Spectroscopy Audra A. Hargett 1, Aaron M. Marcella 1, Huifeng Yu 1, Chao Li 2 , Jared Orwenyo 2, Marcos D. Battistel 1, Lai-Xi Wang 2 and Darón I. Freedberg 1,* 1 Center for Biologics Evaluation and Review, Laboratory of Bacterial Polysaccharides, Food and Drug Administration (FDA), Silver Spring, MD 20993, USA; [email protected] (A.A.H.); [email protected] (A.M.M.); [email protected] (H.Y.); [email protected] (M.D.B.) 2 Department of Chemistry and Biochemistry, University of Maryland, College Park, MD 20742, USA; [email protected] (C.L.); [email protected] (J.O.); [email protected] (L.-X.W.) * Correspondence: [email protected] Abstract: Protein glycosylation is important in many organisms for proper protein folding, signaling, cell adhesion, protein-protein interactions, and immune responses. Thus, effectively determining the extent of glycosylation in glycoprotein therapeutics is crucial. Up to now, characterizing protein glycosylation has been carried out mostly by liquid chromatography mass spectrometry (LC-MS), which requires careful sample processing, e.g., glycan removal or protein digestion and glycopeptide enrichment. Herein, we introduce an NMR-based method to better characterize intact glycoproteins in natural abundance. This non-destructive method relies on exploiting differences in nuclear relaxation to suppress the NMR signals of the protein while maintaining glycan signals. Using RNase B Man5 and RNase B Man9, we establish reference spectra that can be used to determine the different Citation: Hargett, A.A.; Marcella, glycoforms present in heterogeneously glycosylated commercial RNase B.
    [Show full text]
  • Enzymatic Passaging of Human Embryonic Stem Cells Alters Central Carbon Metabolism and Glycan Abundance
    UC San Diego UC San Diego Previously Published Works Title Enzymatic passaging of human embryonic stem cells alters central carbon metabolism and glycan abundance Permalink https://escholarship.org/uc/item/1x27t1sx Journal Biotechnology Journal, 10(10) ISSN 1860-6768 Authors Badur, MG Zhang, H Metallo, CM Publication Date 2015-10-01 DOI 10.1002/biot.201400749 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Biotechnology Biotechnol. J. 2015, 10 DOI 10.1002/biot.201400749 Journal www.biotechnology-journal.com Research Article Enzymatic passaging of human embryonic stem cells alters central carbon metabolism and glycan abundance Mehmet G. Badur1, Hui Zhang1 and Christian M. Metallo1,2 1 Department of Bioengineering, University of California, San Diego, La Jolla, USA 2 Moores Cancer Center, University of California, San Diego, La Jolla, USA To realize the potential of human embryonic stem cells (hESCs) in regenerative medicine and drug Received 17 MAR 2015 discovery applications, large numbers of cells that accurately recapitulate cell and tissue function Revised 10 JUL 2015 must be robustly produced. Previous studies have suggested that genetic instability and epigenetic Accepted 18 AUG 2015 changes occur as a consequence of enzymatic passaging. However, the potential impacts of such Accepted passaging methods on the metabolism of hESCs have not been described. Using stable isotope article online 18 AUG 2015 tracing and mass spectrometry-based metabolomics, we have explored how different passaging reagents impact hESC metabolism. Enzymatic passaging caused significant decreases in glucose utilization throughout central carbon metabolism along with attenuated de novo lipogenesis. In addition, we developed and validated a method for rapidly quantifying glycan abundance and isotopic labeling in hydrolyzed biomass.
    [Show full text]
  • A Site-Specific Map of the Human Plasma Glycome and Its Age And
    www.nature.com/scientificreports OPEN A site‑specifc map of the human plasma glycome and its age and gender‑associated alterations Alexander A. Merleev1, Dayoung Park2,3, Yixuan Xie3, Muchena J. Kailemia3, Gege Xu3, L. Renee Ruhaak3,4, Kyoungmi Kim5, Qiuting Hong3, Qiongyu Li3, Forum Patel1, Yu‑Jui Yvonne Wan6, Alina I. Marusina1, Iannis E. Adamopoulos7,8, Nelvish N. Lal1, Anupum Mitra5, Stephanie T. Le1, Michiko Shimoda1, Guillaume Luxardi1, Carlito B. Lebrilla3,9,10* & Emanual Maverakis1* Alterations in the human glycome have been associated with cancer and autoimmunity. Thus, constructing a site‑specifc map of the human glycome for biomarker research and discovery has been a highly sought‑after objective. However, due to analytical barriers, comprehensive site‑specifc glycoprofling is difcult to perform. To develop a platform to detect easily quantifable, site‑specifc, disease‑associated glycan alterations for clinical applications, we have adapted the multiple reaction monitoring mass spectrometry method for use in glycan biomarker research. The adaptations allow for highly precise site‑specifc glycan monitoring with minimum sample prep. Using this technique, we successfully mapped out the relative abundances of the most common 159 glycopeptides in the plasma of 97 healthy volunteers. This plasma glycome map revealed 796 signifcant (FDR < 0.05) site‑ specifc inter‑protein and intra‑protein glycan associations, of which the vast majority were previously unknown. Since age and gender are relevant covariants in biomarker research, these variables were also characterized. 13 glycopeptides were found to be associated with gender and 41 to be associated with age. Using just fve age‑associated glycopeptides, a highly accurate age prediction model was constructed and validated (r2 = 0.62 ± 0.12).
    [Show full text]
  • N-Glycosylation Processing Pathways Across Kingdoms Cheng-Yu Chung, Natalia I
    SnapShot: N-Glycosylation Processing Pathways across Kingdoms Cheng-Yu Chung, Natalia I. Majewska, Qiong Wang, Jackson T. Paul, and Michael J. Betenbaugh Department of Chemical and Biomolecular Engineering, The Johns Hopkins University, Baltimore, MD 21218, USA Central N-glycosylation processing UDP ALG13 GDP ALG7 ALG14 ALG1 ALG2 ALG11 P P P P P CYTOPLASM P P P P P P GOLGI ER LUMEN GNTI α -Man IA En Bloc ALG3 Transfer ALG9 α-Man IB ER Man I α -Glc I OST ALG10 ALG8 ALG6 ALG12 Asn α -Man IC Asn Asn Asn α -Glc II P P P P P Asn P P P P P ALGs: asparagine-linked N-glycosylation processing enzymes Mammalian Insect Plant Fungi Filamentous fungi α-Man II FUT8 α-1,2-MT XYLT GDP Terminal Asn Asn Asn Asn UDP Asn Galactofuranose GNTII Asn Asn FUT8 f ± α-Gal Asn FUTC3 GNTII High FUT11 α -GALT B14GALTI Och1p Mannose FUT12 glycan α-Man II α-1,2-MT UDP Asn Asn ST3GAL4 Asn Asn GNTIV ST6GAL1 GNTIII GNTV Asn GNase Yeast Hybrid glycan P CMP GNase Asn Asn Tetra- α-Man II Mannosyl- Bisecting antennary phosphate glycan glycan transferase Asn Asn Asn Asn GALT1 Asn ST8SIA2 Core type glycan GNTs B14GALTI α-1,6-MT ST8SIA4 Asn Lewis A structure Polysialylation α-Man PolyLacNAc α-1,2-MT Alternative α-1,3-MT P sialic acid FUT13 ] [ STs Mannosyl- n phosphate Asn Asn Asn transferase Asn Asn Paucimannose Hypermannose glycan Asn Asn Asn glycans Bacteria Archaea Archaea glycan structural diversity Block transfer En Bloc Methanococcus En Bloc Transfer Transfer maripaludis OCH3 Thr OCH AgIB Thr OCH3 3 PERIPLASM PglB B B Asn P - P Asn OSO3 P Asn Asn INNER MEMBRANE P Asn P
    [Show full text]
  • Glycosylation Biomarkers Associated with Age-Related Diseases and Current Methods for Glycan Analysis
    International Journal of Molecular Sciences Review Glycosylation Biomarkers Associated with Age-Related Diseases and Current Methods for Glycan Analysis Beatrix Paton 1, Manuel Suarez 2,* , Pol Herrero 1,* and Núria Canela 1 1 Eurecat, Centre Tecnològic de Catalunya, Centre for Omic Sciences, Joint Unit Eurecat-Universitat Rovira i Virgili, Unique Scientific and Technical Infrastructure (ICTS), 43204 Reus, Spain; [email protected] (B.P.); [email protected] (N.C.) 2 Nutrigenomics Research Group, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43007 Tarragona, Spain * Correspondence: [email protected] (M.S.); [email protected] (P.H.) Abstract: Ageing is a complex process which implies the accumulation of molecular, cellular and organ damage, leading to an increased vulnerability to disease. In Western societies, the increase in the elderly population, which is accompanied by ageing-associated pathologies such as cardiovascular and mental diseases, is becoming an increasing economic and social burden for governments. In order to prevent, treat and determine which subjects are more likely to develop these age-related diseases, predictive biomarkers are required. In this sense, some studies suggest that glycans have a potential role as disease biomarkers, as they modify the functions of proteins and take part in intra- and intercellular biological processes. As the glycome reflects the real-time status of these interactions, its characterisation can provide potential diagnostic and prognostic biomarkers for multifactorial diseases. This review gathers the alterations in protein glycosylation profiles that are Citation: Paton, B.; Suarez, M.; Herrero, P.; Canela, N. Glycosylation associated with ageing and age-related diseases, such as cancer, type 2 diabetes mellitus, metabolic Biomarkers Associated with syndrome and several chronic inflammatory diseases.
    [Show full text]
  • Glycan-Binding Proteins
    molecules Review Resources and Methods for Engineering “Designer” Glycan-Binding Proteins Ruben Warkentin 1,2 and David H. Kwan 1,2,3,* 1 Department of Biology, Centre for Applied Synthetic Biology, and Centre for Structural and Functional Genomics, Concordia University, 7141 Sherbrooke Street West, Montreal, QC H4B 1R6, Canada; [email protected] 2 PROTEO, Quebec Network for Research on Protein Function, Structure, and Engineering, Quebec City, QC G1V 0A6, Canada 3 Department of Chemistry and Biochemistry, Concordia University, 7141 Sherbrooke Street West, Montreal, QC H4B 1R6, Canada * Correspondence: [email protected]; Tel.: +1-514-848-2424 (ext. 7329) Abstract: This review provides information on available methods for engineering glycan-binding proteins (GBP). Glycans are involved in a variety of physiological functions and are found in all domains of life and viruses. Due to their wide range of functions, GBPs have been developed with diagnostic, therapeutic, and biotechnological applications. The development of GBPs has traditionally been hindered by a lack of available glycan targets and sensitive and selective protein scaffolds; however, recent advances in glycobiology have largely overcome these challenges. Here we provide information on how to approach the design of novel “designer” GBPs, starting from the protein scaffold to the mutagenesis methods, selection, and characterization of the GBPs. Keywords: glycobiology; glycan-binding protein; lectins; protein engineering; glycans; carbohy- drates; directed evolution; glycan immobilization Citation: Warkentin, R.; Kwan, D.H. Resources and Methods for Engineering “Designer” Glycan 1. Introduction -Binding Proteins. Molecules 2021, 26, Glycans—a broad term describing carbohydrates, including oligosaccharides and 380. https://doi.org/10.3390/ polysaccharides—are the third class of important biological macromolecules following molecules26020380 nucleic acids and proteins [1].
    [Show full text]